Administration of Fibrinogen Concentrate for Refractory Bleeding

Inclusion Criteria: * Patient affiliated to a social security regimen or beneficiary of the same * Signed written informed consent form * Confirmed diagnosis of a hematological malignancy and undergoing intensive chemotherapy, autologous stem cell transplantation or allogeneic stem cell transplantation * Grade ≥ II hemorrhagic symptoms according to WWorld Health Organization classification * Failure or impossibility to use Human Leucocyte Antigen-matched platelet unit * Body weight between 38 and 78 Kgs * Transfusion refractoriness as defined by Corrected count increment ≤ 5 and platelet level \< 20.109.L-1 Exclusion Criteria: * Pregnant women * Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent * Refusing participation * Patient presenting non-malignant hematological disease * Patient with high plasmatic concentration of fibrinogen (\>5g/L) * Patient who received fibrinogen within 20 days before inclusion * Contra-indication to fibrinogen (fibrinogen concentrate) or any excipient (fibrinogen concentrate) * Patient with disseminated intravascular coagulopathy * Patient with thromboembolic history * Patient who received L-Asparaginase or acquired hypofibrinogenemia following treatment by L-Asparaginase * Patient with known risk of thrombophilia (deficiency for antithrombin 3, C protein or factor V) * Patient with anti-thrombotic treatment (anti-platelet or anti-coagulant th…